How quickly does Wegovy take effect — and what will you actually notice first?

Week one: you've just injected, here's what is already happening

Imagine it's Sunday evening. You've stored your pen in the fridge door, clicked through the steps, done your first injection into your abdomen, and now you're wondering whether anything is actually occurring. The answer is: yes, quietly. Semaglutide begins binding to GLP-1 receptors almost immediately after the first dose. Those receptors sit in the gut and the brain, and their activation slows gastric emptying and begins dampening appetite signals. You probably won't feel dramatically different by Monday morning, the 0.25mg starting dose is deliberately modest, calibrated to let your body adjust rather than to drive weight loss. What many people do notice in the first one to two weeks is a mild reduction in how hungry they feel between meals, or that they feel full before finishing a plate. Some notice nausea, particularly after meals, as the stomach empties more slowly than usual. That tends to settle within days for most people, though it can linger. The nausea is not a sign something is wrong, it's the most common early signal that the medicine is active. If it's severe or persistent, your prescriber needs to know.

For more detail on the sensations people report in these early days, our page on how quickly you feel the effects of Wegovy covers that individual variation in depth.

Weeks four to twelve: the dose rises and the weight begins to shift

The real story of Wegovy's timeline is the titration schedule. Your prescriber moves the dose upward roughly every four weeks: from 0.25mg to 0.5mg, then 1.0mg, then 1.7mg, and ultimately 2.4mg, or the newer 7.2mg option for some patients, following the MHRA's approval of that higher dose. Each step brings a modest increase in the appetite-suppressing effect, and it's usually during this phase, between weeks four and twelve, that people start seeing consistent week-on-week weight change.

What's happening physiologically is a compounding effect: you're eating less because hunger signals are quieter, portions feel satisfying sooner, and the craving for high-calorie foods often reduces. The medicine is working alongside the reduced-calorie diet and increased activity that form part of the treatment plan, it's not producing results independently of those. By the end of three months, most people who are responding to treatment have lost somewhere between 5% and 10% of their starting weight, though this varies considerably between individuals. If you're curious about how long for Wegovy to take effect before clinically significant loss becomes apparent, the full timeline of how long Wegovy takes to work addresses that in detail.

Gastrointestinal side effects (nausea, loose stools, indigestion) tend to peak around dose increases and then ease. Keeping well hydrated and eating smaller meals more slowly helps many people manage this period. Your prescriber can discuss whether to hold a dose longer if side effects are pronounced.

Months three to seventeen: reaching maintenance and the STEP 1 evidence

The published trial evidence gives the clearest picture of what sustained treatment looks like. In the STEP 1 study, published in the New England Journal of Medicine, adults with obesity using semaglutide 2.4mg weekly for 68 weeks alongside lifestyle changes lost around 15% of body weight on average. That's a gradual, sustained reduction accumulated over more than a year, not a fast drop. If you're wondering how quickly Wegovy works for weight loss, the evidence shows it is steepest in the first six months, slows as the body adapts, and then plateaus at or near the maintenance dose.

Wegovy's newer 7.2mg dose, approved by the MHRA on 14 April 2026, has shown average losses of around 20.7% over 72 weeks in trials, narrowing the gap with tirzepatide. Specific dose availability is confirmed at the point of clinical consultation. For a broader view of how Wegovy compares and what the treatment landscape looks like, the Wegovy overview page covers the full picture, including the MASH liver-disease indication approved in July 2026.

One thing the trials also show: weight begins to return if treatment stops without the lifestyle changes being embedded. That's why prescribers at nume, sorry, at nume review every repeat order clinically, and why aftercare support runs seven days a week. The prescription isn't a one-and-done transaction.

If you're weighing up whether this treatment suits your situation, exploring the full range of weight-loss treatments is a natural next step. Suitability depends on clinical assessment; a prescriber reviews the complete picture, not just BMI.

When to contact your prescriber (and when progress feels slow

Slow initial progress is common and rarely a sign the medicine isn't working) it often just means you're still in the titration phase. People sometimes ask how quickly Wegovy works, and NICE's guidance on semaglutide offers a useful benchmark, noting that treatment should be reviewed if less than 5% weight loss has occurred after six months at the maintenance dose; that's the clinical threshold for reconsidering the plan, not a reason to stop at week six because the scales haven't shifted as fast as you hoped.

What does warrant urgent contact is severe, persistent stomach pain that radiates toward the back, this can indicate pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines. Other reasons to seek medical help promptly include signs of a serious allergic reaction, gallbladder symptoms, or significant dehydration from vomiting or diarrhoea. Any concerns between reviews can go to our aftercare team, available seven days a week.

If you'd like to understand the eligibility criteria before considering a consultation, check your eligibility through a free consultation, a GPhC-registered prescriber reads every form the same day it's submitted.